Stock Price & Analysis

Analysis and Insights

Based on the provided data, here's a concise analysis:

Analyst Sentiment:

• Globus Medical (GMED) has a consensus Buy rating with a price target of $115.00, indicating a 33.1% upside from its current price of $71.30.
• Analysts highlight strong financial performance, with quarterly revenue of $657.29 million and net profit of $26.51 million, showing growth compared to last year.

Technical Analysis:

• The stock is trading above its 50-day and 200-day moving averages, indicating a bullish trend.
• The RSI (14) is at 46.46, suggesting the stock is not overbought.

Valuation:

• The stock is part of the iShares Core S&P U.S. Growth ETF (IUSG), which has an implied analyst target price of $163.66, indicating a 23.67% upside.

Conclusion:

Given the strong analyst consensus, positive financial performance, and bullish technical indicators, GMED is a buy.

Globus Medical (GMED) is expected to reach a price target of $110 by 2025, driven by strong revenue growth and successful acquisitions. Analysts predict the stock will rise to $105-$115, supported by its robust financial performance and positive analyst sentiment.

The S1 support level for GMED Stock is $69.78 ,The R1 resistant level for GMED Stock is $75.26.

As of the end of day on 2025-03-24, the price of GMED Stock was $76.05.

The target price for GMED Stock according to analyst rating is 99.42, with the highest price target at 115.00 and the lowest at 90.00. Analysts have a Moderate Buy rating on GMED Stock overall.

The market cap of GMED is $10.5B.

Analysis and Insights

Globus Medical (GMED) appears overvalued based on its current valuation metrics and financial performance.

1. High Valuation Multiples: GMED's forward P/E ratio of 99.59 and EV/EBITDA of 22.17 are significantly higher than industry averages, suggesting elevated expectations.

2. Inconsistent Profitability: While revenue growth is strong, net income has been volatile, with Q1 2024 reporting a net loss of $7.17 million despite increasing revenues.

3. Analyst Sentiment: Analysts maintain a Moderate Buy rating with a $99.42 average price target, indicating a 33.1% upside potential, but this also reflects cautious optimism.

4. Financial Health: The company has a healthy current ratio of 2.33 and manageable debt levels, but its ROE of 10.83% is below historical averages.

5. Conclusion: GMED's high valuation and inconsistent profitability raise concerns about overvaluation, despite positive revenue growth and analyst optimism.

Globus Medical, Inc. is a medical device company that develops and commercializes healthcare solutions with a focus on improving the quality of life of patients with musculoskeletal disorders. The Company offers a portfolio of differentiated technologies that are used to treat a variety of musculoskeletal conditions. Musculoskeletal Solutions consist primarily of implantable devices, biologics, accessories, and surgical instruments used in a range of spinal, orthopedic and neurosurgical procedures. Its spine products address the majority of conditions affecting the spine, including degenerative conditions, deformity, tumors, and trauma. It provides solutions that facilitate both open and minimally invasive surgery (MIS) techniques. It includes traditional fusion implants, such as pedicle screws and rod systems. Its orthopedic trauma solutions are designed to treat a variety of orthopedic fracture patterns and patient anatomies in the upper and lower extremities, as well as the hip.

Globus Medical (GMED) stock is predicted to reach $140-$160 by 2030, driven by strong financial performance, strategic acquisitions like Nevro, and continued innovation in musculoskeletal solutions. The company's expanding product portfolio and global reach position it for sustained growth.

GMED has a total of 5000 employees.